AR011521A1 - Un derivado de la prolil-3-(2-naftil) alanil-n-bencil-n-metilamida, un procedimiento para su preparacion y una composicion farmaceutica que lo comprende - Google Patents

Un derivado de la prolil-3-(2-naftil) alanil-n-bencil-n-metilamida, un procedimiento para su preparacion y una composicion farmaceutica que lo comprende

Info

Publication number
AR011521A1
AR011521A1 ARP980100097A ARP980100097A AR011521A1 AR 011521 A1 AR011521 A1 AR 011521A1 AR P980100097 A ARP980100097 A AR P980100097A AR P980100097 A ARP980100097 A AR P980100097A AR 011521 A1 AR011521 A1 AR 011521A1
Authority
AR
Argentina
Prior art keywords
formula
compound
derivative
methylamide
pharmaceutical composition
Prior art date
Application number
ARP980100097A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR011521A1 publication Critical patent/AR011521A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/22Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP980100097A 1997-01-14 1998-01-09 Un derivado de la prolil-3-(2-naftil) alanil-n-bencil-n-metilamida, un procedimiento para su preparacion y una composicion farmaceutica que lo comprende AR011521A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9700597.9A GB9700597D0 (en) 1997-01-14 1997-01-14 Organic compounds

Publications (1)

Publication Number Publication Date
AR011521A1 true AR011521A1 (es) 2000-08-30

Family

ID=10805904

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100097A AR011521A1 (es) 1997-01-14 1998-01-09 Un derivado de la prolil-3-(2-naftil) alanil-n-bencil-n-metilamida, un procedimiento para su preparacion y una composicion farmaceutica que lo comprende

Country Status (14)

Country Link
US (1) US6107293A (https=)
EP (1) EP0964867B1 (https=)
JP (2) JP4306804B2 (https=)
AR (1) AR011521A1 (https=)
AT (1) ATE290546T1 (https=)
AU (1) AU5764298A (https=)
CA (1) CA2278057C (https=)
CO (1) CO4950614A1 (https=)
DE (1) DE69732715T2 (https=)
ES (1) ES2239368T3 (https=)
GB (1) GB9700597D0 (https=)
PT (1) PT964867E (https=)
WO (1) WO1998031704A2 (https=)
ZA (1) ZA98256B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426331B1 (en) 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
JP2002542151A (ja) 1999-02-18 2002-12-10 科研製薬株式会社 成長ホルモン分泌促進物質としての新規なアミド誘導体
WO2001083517A1 (en) * 2000-05-03 2001-11-08 Tularik Inc. Stat4 and stat6 binding dipeptide derivatives
US6884782B2 (en) 2000-11-08 2005-04-26 Amgen Inc. STAT modulators
US20070219214A1 (en) * 2006-02-01 2007-09-20 Solvay Pharmaceuticals Gmbh Dual NK2/NK3-antagonists, pharmaceutical compositions comprising them, and processes for their preparation
US8426386B2 (en) 2006-10-16 2013-04-23 Lion Corporation NK1 receptor antagonist composition
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
US20210015834A1 (en) 2018-02-26 2021-01-21 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210669A (en) * 1983-12-27 1988-05-30 Syntex Inc Benzoxazin-4-one derivatives and pharmaceutical compositions
GB8929070D0 (en) * 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
FR2719312B1 (fr) * 1994-04-28 1996-06-14 Adir Nouveau pseudopeptides dérivés de neurokinines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
US6107293A (en) 2000-08-22
EP0964867A2 (en) 1999-12-22
WO1998031704A2 (en) 1998-07-23
CA2278057C (en) 2004-05-04
ATE290546T1 (de) 2005-03-15
CA2278057A1 (en) 1998-07-23
JP3817256B2 (ja) 2006-09-06
PT964867E (pt) 2005-07-29
DE69732715T2 (de) 2006-04-13
GB9700597D0 (en) 1997-03-05
CO4950614A1 (es) 2000-09-01
ZA98256B (en) 1998-07-14
JP2006089499A (ja) 2006-04-06
WO1998031704A3 (en) 1998-09-11
JP4306804B2 (ja) 2009-08-05
EP0964867B1 (en) 2005-03-09
JP2000516257A (ja) 2000-12-05
DE69732715D1 (de) 2005-04-14
ES2239368T3 (es) 2005-09-16
AU5764298A (en) 1998-08-07

Similar Documents

Publication Publication Date Title
HU9200823D0 (en) Process for the production of cyclical carbamide derivatives and medical preparations containing them as active agents
PT99317A (pt) Processo para a preparacao de novos compostos peptidicos e de composicoes farmaceuticas que os contem
AR017021A1 (es) Acido 2-hidroxiacetico
AR031828A2 (es) Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia
EA200000682A1 (ru) Новые ацилгуанидиновые производные в качестве ингибиторов резорбции костной ткани и антагонистов витронектиновых рецепторов
ES2043781T3 (es) Un procedimiento para la preparacion de nuevos derivados de 2beta-morfolino-androstano.
AR029150A1 (es) Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende.
BR0109109A (pt) Composto, uso do mesmo, processo para prepará-lo, composição farmacêutica, e, método de tratar um estado doentio mediado por ccr5 em mamìferos
AR011521A1 (es) Un derivado de la prolil-3-(2-naftil) alanil-n-bencil-n-metilamida, un procedimiento para su preparacion y una composicion farmaceutica que lo comprende
ES2038172T3 (es) Procedimiento para preparar carboxamidas heterociclicas.
BR0215277A (pt) Dicetopiperazinas substituìdas como antagonistas da oxitocina
MY113863A (en) Method for preparing n, n' - disubstituted cyclic ureas
AR037521A1 (es) Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion
AR027578A1 (es) Derivados de indano
ES2114722T3 (es) Procedimiento para preparar intermedios derivados del acido benzoico y agentes farmaceuticos benzotiofenos.
ES2080726T3 (es) Compuestos aromaticos o heteroaromaticos nitrosustituidos para su utilizacion en el tratamiento del cancer.
EA200100969A1 (ru) Новые соединения циклобутендиона, способ их получения и содержащие их фармацевтические композиции
CO5590934A2 (es) Procedimiento de preparacion de derivados de equinocandina
FR2393577A1 (fr) Medicament a base d'acide b-(p-halogenophenyl)-g-aminobutyrique destine au traitement de la nevrose d'angoisse
UY24697A1 (es) Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa
BR0010225A (pt) Composto de amida, processo para prepará-lo, composição farmacêutica compreendendo dito composto, método de tratamento e uso
ES8506651A1 (es) Un metodo de preparar fenilalquil(piperazinil u homopiperazinil)propil-(ureas y tioureas) sustituidas
NO175679C (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv, substituert aminforbindelse
EA200000374A2 (ru) Новые соединения 2,3-метаноаминокислоты, способ их получения и содержащие их фармацевтические композиции
DE3684186D1 (de) Verwendung von pharmaceutischen zusammensetzungen fuer die herstellung von arzneimitteln fuer die behandlung psychiatrischer stoerungen.

Legal Events

Date Code Title Description
FG Grant, registration